NSE / BSEHealthcare
β‚Ή3190.50-8.30-0.26%
P/E25.4Mkt Capβ‚Ή9.39 K CrEV/EBITDA0.0

Sanofi India Ltd

P/E25.4Mkt Capβ‚Ή9.39 K CrEV/EBITDA0.0
Company Profile

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, epilepsy, anti-infectives, and central nervous system, as well as allergy, pain care, digestive, and nutritional health under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products to approximately 24 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 26 Aug 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
β€”
β€”
EV / Sales
β€”
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
β€”
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
β€”
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–Ό 37.41% over 1Y
Monthly Returns

Historically, May has averaged the highest return (+3.9%); Sep the lowest (-4.9%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-1.8%Neutral MonthJan 2026: -1.80%-1.4%Neutral MonthFeb 2026: -1.36%-19.1%Negative MonthMar 2026: -19.08%+6.3%Positive MonthApr 2026: +6.27%-8.8%Negative MonthMay 2026: -8.84%+9.6%Positive MonthJun 2026: +9.64%-2.5%Negative MonthJul 2026: -2.51%-3.9%*Negative MonthAug 2026: -3.93%β€”β€”β€”β€”
2025-9.7%Negative MonthJan 2025: -9.69%-9.1%Negative MonthFeb 2025: -9.08%+14.0%Positive MonthMar 2025: +13.96%+3.6%Positive MonthApr 2025: +3.58%+4.7%Positive MonthMay 2025: +4.66%+2.7%Positive MonthJun 2025: +2.69%-8.5%Negative MonthJul 2025: -8.45%-12.0%Negative MonthAug 2025: -11.95%-9.5%Negative MonthSep 2025: -9.50%+2.8%Positive MonthOct 2025: +2.78%-8.1%Negative MonthNov 2025: -8.12%-6.8%Negative MonthDec 2025: -6.84%
2024+7.4%Positive MonthJan 2024: +7.42%-0.6%Neutral MonthFeb 2024: -0.59%-5.8%Negative MonthMar 2024: -5.76%+2.5%Positive MonthApr 2024: +2.54%+3.8%Positive MonthMay 2024: +3.76%-24.8%Negative MonthJun 2024: -24.82%+1.6%Neutral MonthJul 2024: +1.64%+3.2%Positive MonthAug 2024: +3.16%+3.7%Positive MonthSep 2024: +3.67%-3.9%Negative MonthOct 2024: -3.86%-5.7%Negative MonthNov 2024: -5.75%-4.3%Negative MonthDec 2024: -4.31%
2023-6.0%Negative MonthJan 2023: -6.05%+6.1%Positive MonthFeb 2023: +6.08%-1.5%Neutral MonthMar 2023: -1.55%-2.9%Negative MonthApr 2023: -2.92%+21.9%Positive MonthMay 2023: +21.90%+1.7%Neutral MonthJun 2023: +1.69%+1.3%Neutral MonthJul 2023: +1.28%+1.6%Neutral MonthAug 2023: +1.59%+1.4%Neutral MonthSep 2023: +1.40%+5.0%Positive MonthOct 2023: +4.96%+6.1%Positive MonthNov 2023: +6.07%+0.6%Neutral MonthDec 2023: +0.55%
2022-4.3%Negative MonthJan 2022: -4.28%-3.9%Negative MonthFeb 2022: -3.87%+3.4%Positive MonthMar 2022: +3.35%-7.0%Negative MonthApr 2022: -7.04%-2.0%Neutral MonthMay 2022: -1.98%-5.9%Negative MonthJun 2022: -5.90%-1.6%Neutral MonthJul 2022: -1.59%-2.3%Negative MonthAug 2022: -2.28%-6.5%Negative MonthSep 2022: -6.48%-3.0%Negative MonthOct 2022: -3.03%+1.8%Neutral MonthNov 2022: +1.79%+2.4%Positive MonthDec 2022: +2.39%
2021β€”β€”β€”β€”β€”-0.5%Neutral MonthJun 2021: -0.50%+8.8%Positive MonthJul 2021: +8.82%+7.8%Positive MonthAug 2021: +7.80%-13.6%Negative MonthSep 2021: -13.58%+7.0%Positive MonthOct 2021: +7.00%-4.7%Negative MonthNov 2021: -4.72%-0.7%Neutral MonthDec 2021: -0.69%
AvgΒ±SD-2.9%Β±5.8%-1.8%Β±4.9%-1.8%Β±10.9%+0.5%Β±4.8%+3.9%Β±10.2%-2.9%Β±10.8%-0.1%Β±5.2%-0.9%Β±6.2%-4.9%Β±6.5%+1.6%Β±4.3%-2.1%Β±5.3%-1.8%Β±3.3%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 0.780x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ€”
EBITDA Growthβ€”
Net Profitβ€”
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”
Revenue CAGR 5Y0.0%
EBITDA CAGR 5Y0.0%
Net Profit CAGR 5Y0.0%
NP Growth 1Y-31.3%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β€”β€”β€”β€”β€”β€”β€”β€”
Mar 2024β‚Ή2.01 K Crβ€”β‚Ή414.00 Crβ€”β€”β€”0.9%-31.3%
Mar 2023β‚Ή2.00 K Crβ€”β‚Ή603.00 Crβ€”β€”β€”-27.9%-2.9%
Mar 2022β‚Ή2.77 K Crβ€”β‚Ή621.00 Crβ€”β€”β€”-6.3%-34.2%
Mar 2021β‚Ή2.96 K Crβ€”β‚Ή944.00 Crβ€”β€”β€”1.9%97.5%
Mar 2020β‚Ή2.90 K Crβ€”β‚Ή478.00 Crβ€”β€”β€”-5.5%15.5%
Mar 2019β‚Ή3.07 K Crβ€”β‚Ή414.00 Crβ€”β€”β€”10.8%8.7%
Mar 2018β‚Ή2.77 K Crβ€”β‚Ή381.00 Crβ€”β€”β€”12.6%16.9%
Mar 2017β‚Ή2.46 K Crβ€”β‚Ή326.00 Crβ€”β€”β€”3.9%7.2%
Mar 2016β‚Ή2.37 K Crβ€”β‚Ή304.00 Crβ€”β€”β€”7.9%-5.6%

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024TTM
Revenue / Net Sales1,8091,9772,1932,3672,4602,7713,0712,9022,9572,7701,9962,0131,932
Total Expenses1,4111,6391,8171,8321,9212,1462,4032,1862,1942,0661,5081,5221,413
EBIT / Operating Profit398339376535538625667716762704488491519
OPM %22171723222322252625242427
Other Income831312186679883345564204318794
Finance Costs0002110222222
Depreciation & Amortisation9297113119102103100826742363737
Profit Before Tax3883734814805156106006771,258864767531484
Tax %322933373738312925282122-
Net Profit / PAT265264322304326381414478944621603414356
EPS (β‚Ή)115.30114.61139.78132.26141.74165.48180.09207.65410.61269.83262.26179.78154.92
Dividend Payout %3939465150511941761192116465-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
Sanofi India Ltdthis co.β‚Ή9.39 K Crβ‚Ή2.01 K Cr25.4011.990.000.9%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of Sanofi India Ltd and the metrics that matter.

Browse the full Equiscale Academy